Antibodies are Y-shaped proteins produced by B cells that bind to specific antigens with high precision. Their applications span diagnostics, therapeutics, and research tools .
Structure: Composed of two heavy and two light chains, with variable regions (CDRs) determining antigen specificity .
Key Functions: Neutralization, agglutination, complement activation, and opsonization .
The identifier Os10g0537100 suggests a gene locus in Oryza sativa (rice), possibly encoding a protein involved in stress response, growth, or metabolic pathways. Antibodies against such targets are typically used to:
Study protein expression via Western blotting or immunohistochemistry .
Investigate protein-protein interactions via immunoprecipitation .
Antibody specificity remains a critical issue. For example:
Validation Requirements:
Historical Issues:
| Antibody Type | Success Rate (Western Blot) | Common Pitfalls |
|---|---|---|
| Recombinant | 75% | Low batch variability |
| Polyclonal | 40% | Non-specific binding |
| Monoclonal | 55% | Epitope masking |
While Os10g0537100 is not a therapeutic target, approved antibody therapies highlight design principles:
| Name (INN) | Target | Format | Application |
|---|---|---|---|
| Eculizumab | C5 | Humanized IgG2/IgG4 hybrid | Paroxysmal nocturnal hemoglobinuria |
| Omalizumab | IgE | Humanized IgG1 | Asthma |
| Ofatumumab | CD20 | Human IgG1 | Chronic lymphocytic leukemia |
Fc modifications (e.g., S228P hinge stabilization) to enhance half-life .
Species Origin: Humanized or fully human antibodies reduce immunogenicity .
KEGG: osa:107278273